Haemonetics Gestion
Gestion contrôle des critères 3/4
Le PDG Haemonetics est Chris Simon, nommé en May2016, a un mandat de 8.5 ans. La rémunération annuelle totale est $ 11.55M, composée du salaire de 9.4% et des bonus 90.6%, y compris les actions et options de la société. détient directement 0.55% des actions de la société, d'une valeur de $ 23.47M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.3 ans et 7 ans.
Informations clés
Chris Simon
Directeur général
US$11.5m
Rémunération totale
| Pourcentage du salaire du PDG | 9.4% |
| Durée du mandat du directeur général | 8.5yrs |
| Propriété du PDG | 0.6% |
| Durée moyenne d'occupation des postes de direction | 3.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7yrs |
Mises à jour récentes de la gestion
Recent updates
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Sep 09
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
Aug 14Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Jul 18Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Jun 21Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Apr 30Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Apr 12Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Mar 07Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Mar 06The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Feb 15The Price Is Right For Haemonetics Corporation (NYSE:HAE)
Jan 01Haemonetics: Solid Performance Of This Blood Play
Nov 22Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
Nov 14Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Oct 13Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains
Aug 09Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors
Aug 09An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued
Jul 25Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?
Mar 19Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer
Feb 16Haemonetics: Earnings Rate Of Change Justifies High Multiples
Feb 01We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?
Dec 15Haemonetics Q2 2023 Earnings Preview
Nov 04Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly
Oct 04Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy
Sep 06Haemonetics reaches new 52-week high; shares up 41% YTD
Aug 24Haemonetics reports Q2 earnings beat; raises FY22 guidance
Aug 10A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)
Aug 10Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly
Jul 03Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 28 2024 | n/a | n/a | US$124m |
| Jun 29 2024 | n/a | n/a | US$115m |
| Mar 30 2024 | US$12m | US$1m | US$118m |
| Dec 30 2023 | n/a | n/a | US$127m |
| Sep 30 2023 | n/a | n/a | US$128m |
| Jul 01 2023 | n/a | n/a | US$137m |
| Apr 01 2023 | US$11m | US$1m | US$115m |
| Dec 31 2022 | n/a | n/a | US$96m |
| Oct 01 2022 | n/a | n/a | US$86m |
| Jul 02 2022 | n/a | n/a | US$68m |
| Apr 02 2022 | US$9m | US$945k | US$43m |
| Jan 01 2022 | n/a | n/a | US$23m |
| Oct 02 2021 | n/a | n/a | US$31m |
| Jul 03 2021 | n/a | n/a | US$64m |
| Apr 03 2021 | US$9m | US$963k | US$79m |
| Dec 26 2020 | n/a | n/a | US$108m |
| Sep 26 2020 | n/a | n/a | US$106m |
| Jun 27 2020 | n/a | n/a | US$96m |
| Mar 28 2020 | US$9m | US$937k | US$77m |
| Dec 28 2019 | n/a | n/a | US$80m |
| Sep 28 2019 | n/a | n/a | US$68m |
| Jun 29 2019 | n/a | n/a | US$49m |
| Mar 30 2019 | US$9m | US$894k | US$55m |
| Dec 29 2018 | n/a | n/a | US$46m |
| Sep 29 2018 | n/a | n/a | US$21m |
| Jun 30 2018 | n/a | n/a | US$23m |
| Mar 31 2018 | US$8m | US$858k | US$46m |
Rémunération vs marché: La rémunération totale de Chris ($USD 11.55M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 6.57M ).
Rémunération et revenus: La rémunération de Chris a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Chris Simon (60 yo)
8.5yrs
Titularisation
US$11,545,113
Compensation
Mr. Christopher A. Simon, also known as Chris, has been the Chief Executive Officer and President of Haemonetics Corporation since May 16, 2016 and has been its Director since May 2016. He joined Haemoneti...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 8.5yrs | US$11.55m | 0.55% $ 23.5m | |
| CFO, Executive VP & Financial Officer | 2.6yrs | US$3.15m | 0.0095% $ 404.7k | |
| Executive VP | 7.7yrs | US$3.07m | 0.039% $ 1.7m | |
| Executive Vice President of Global Manufacturing & Supply Chain | 6.3yrs | US$2.43m | 0.039% $ 1.7m | |
| VP, Chief Accounting Officer & Principal Accounting Officer | 2.1yrs | pas de données | 0.00027% $ 11.5k | |
| Senior Director of Investor Relations | 5.1yrs | pas de données | pas de données | |
| Senior Vice President of Strategy & Corporate Development | 1.6yrs | pas de données | pas de données | |
| Senior VP & Chief Human Resources Officer | 3.3yrs | pas de données | 0.023% $ 997.6k | |
| Senior VP & Chief Medical Officer | 1.6yrs | pas de données | pas de données | |
| President of Global Hospital | 5.2yrs | US$2.48m | 0.036% $ 1.5m | |
| Senior Vice President of Global Quality Assurance | 3.3yrs | pas de données | pas de données | |
| President of Global Plasma & Blood Center | 2.1yrs | pas de données | 0.0036% $ 154.0k |
3.3yrs
Durée moyenne de l'emploi
53.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de HAE est considérée comme expérimentée (ancienneté moyenne 3.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 8.2yrs | US$11.55m | 0.55% $ 23.5m | |
| Independent Director | 7.1yrs | US$295.73k | 0.036% $ 1.5m | |
| Independent Director | 4.6yrs | US$283.73k | 0.016% $ 702.0k | |
| Independent Chairman | 6.8yrs | US$449.98k | 0.024% $ 1.0m | |
| Independent Director | 5.6yrs | US$269.95k | 0.019% $ 827.8k | |
| Independent Director | 18.8yrs | US$280.73k | 0.032% $ 1.4m | |
| Independent Director | 10.3yrs | US$292.95k | 0.036% $ 1.5m | |
| Independent Director | 3.3yrs | US$272.95k | 0.012% $ 493.0k | |
| Member of Scientific Advisory Council | no data | pas de données | pas de données | |
| Member of Scientific Advisory Council | no data | pas de données | pas de données | |
| Member of Scientific Advisory Council | no data | pas de données | pas de données | |
| Member of Scientific Advisory Council | no data | pas de données | pas de données |
7.0yrs
Durée moyenne de l'emploi
70yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de HAE sont considérés comme expérimentés (ancienneté moyenne 7 ans).